Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →🤖 ML Fraud Detection Score: 90%
Machine learning model identifies prescribing patterns consistent with confirmed fraud cases. This is a statistical indicator, not an accusation.
Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
18,205
Total Claims
$1.9M
Drug Cost
737
Beneficiaries
$2,602
Cost/Patient
Risk Score Breakdown 18/100
Score components are additive. Read full methodology
Peer Comparison vs. 110,156 Internal Medicine providers
+162%
Opioid rate vs peers
5.9% vs 2.2% avg
+84%
Cost per patient vs peers
$2,602 vs $1,411 avg
+27%
Brand preference vs peers
13.5% vs 10.6% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
Opioid Prescribing
5.9%
Opioid Rate
1,066
Opioid Claims
$30K
Opioid Cost
2.8%
Long-Acting Rate
Brand vs Generic
Brand: 2,425 claims · $1.5M
Generic: 15,476 claims · $353K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Sitagliptin Phosphate | 135 | $155K |
| Empagliflozin | 128 | $124K |
| Apixaban | 129 | $107K |
| Insulin Aspart | 89 | $99K |
| Semaglutide | 63 | $86K |
| Fluticasone/Umeclidin/Vilanter | 98 | $81K |
| Dulaglutide | 54 | $71K |
| Dapagliflozin Propanediol | 53 | $69K |
| Insulin Detemir | 51 | $53K |
| Linagliptin | 69 | $51K |
| Insulin Glargine,hum.Rec.Anlog | 69 | $48K |
| Insulin Lispro | 38 | $39K |
| Rivaroxaban | 23 | $35K |
| Insulin Degludec | 49 | $31K |
| Semaglutide | 19 | $28K |
Prescribing Profile
Patient Profile
72
Avg Age
55%
Female
1.74
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About